 |
Vol.59 No.5 contents | Japanese/English |
 | Full Text of PDF (309K) Article in Japanese |
- Original Article -
Efficacy and Safety of Salvage Surgery After Molecular Targeting Drug Treatment for Advanced Lung Cancer
Naoya Ishibashi1, Toshiharu Tabata1, Ryo Nonomura1, Yutaka Oshima1, Takanobu Sasaki1, Hideki Mitomo1, Takafumi Sugawara1, Motoyasu Sagawa2, Takashi Kondo11Department of Thoracic Surgery, 2Division of Endoscopy, Tohoku Medical and Pharmaceutical University Hospital, Japan
Objective. The efficacy and safety of salvage surgery after down-staging following molecular targeting drug therapy were retrospectively evaluated. Methods. We reviewed the medical records of cases in which salvage surgery was performed for residual tumors that were diagnosed as inoperable and which responded to molecular targeting drugs. The records were anonymized, then a database was created and analyzed it. Results. Among 580 lung cancer surgeries performed at our hospital from January 2011 to March 2017, we extracted and analyzed the cases of 8 patients who underwent surgery after initially being classified as inoperable, following a successful response to molecular targeting drugs. There were no serious side effects or perioperative complications during molecular targeting drug therapy. The pathological effect of molecular targeting drug therapy was classified as follows; Ef.1a (n=2), Ef.1b (n=1), Ef.2 (n=4), and Ef.3 (n=1). Four of the 8 patients were alive (2 remained free of disease and 2 were alive with cancer), while 4 patients died of cancer. The median postoperative survival was 53 months (1-87 months). Conclusion. In cases involving patients with unresectable advanced lung cancer, salvage surgery after treatment with molecular targeting drugs was able to achieve relatively good outcomes without fatal complications.
key words: Lung cancer, Salvage surgery, Molecular targeting drug
Received: April 27, 2019
Accepted: July 18, 2019
JJLC 59 (5): 463-466, 2019
